Cargando…

Hepatitis C Resistance-Associated Substitutions Among People Who Inject Drugs Treated With Direct-Acting Antiviral-Containing Regimens

BACKGROUND: Resistance-associated substitutions (RASs) to HCV direct-acting antivirals (DAAs) can contribute to virologic failure and limit retreatment options. People who inject drugs (PWID) are at highest risk for transmission of resistant virus. We report on RASs at baseline and after virologic f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Akiyama, Matthew J, Riback, Lindsey, Reeves, Jacqueline D, Lie, Yolanda S, Agyemang, Linda, Norton, Brianna L, Arnsten, Julia H, Litwin, Alain H
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Major Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8530260/ https://www.ncbi.nlm.nih.gov/pubmed/34692891 http://dx.doi.org/10.1093/ofid/ofab474

Ejemplares similares

Declines in Depressive Symptoms Among People who Inject Drugs Treated With Direct-Acting Antivirals While on Opioid Agonist Therapy
por: Pericot-Valverde, Irene, et al.
Publicado: (2020)

Low Adherence Achieves High HCV Cure Rates Among People Who Inject Drugs Treated With Direct-Acting Antiviral Agents
por: Norton, Brianna L, et al.
Publicado: (2020)

Rationale, design, and methodology of a trial evaluating three models of care for HCV treatment among injection drug users on opioid agonist therapy
por: Akiyama, Matthew J., et al.
Publicado: (2018)

Sofosbuvir-Based Direct-Acting Antiviral Therapies for HCV in People Receiving Opioid Substitution Therapy: An Analysis of Phase 3 Studies
por: Grebely, Jason, et al.
Publicado: (2018)

Reduction in Depressive Symptoms in People who Inject Drugs who Are Cured of Hepatitis C Virus Infection: The HERO Study
por: Pericot-Valverde, Irene, et al.
Publicado: (2023)

More intensive hepatitis C virus care models promote adherence among people who inject drugs with active drug use: The PREVAIL study
por: Heo, Moonseong, et al.
Publicado: (2022)

Artificial Intelligence Platform Demonstrates High Adherence in Patients Receiving Fixed-Dose Ledipasvir and Sofosbuvir: A Pilot Study
por: Litwin, Alain H, et al.
Publicado: (2020)

Factors and HCV treatment outcomes associated with smoking among people who inject drugs on opioid agonist treatment: secondary analysis of the PREVAIL randomized clinical trial
por: Pericot-Valverde, Irene, et al.
Publicado: (2020)

Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB Cohort( )
por: Hewison, Catherine, et al.
Publicado: (2022)

Sitafloxacin-Containing Regimen for the Treatment of Refractory Mycobacterium avium Complex Lung Disease
por: Asakura, Takanori, et al.
Publicado: (2019)

Direct-Acting Antivirals Improve Access to Care and Cure for Patients With HIV and Chronic HCV Infection
por: Collins, Lauren F, et al.
Publicado: (2017)

Re-treatment of Hepatitis C Infection After Multiple Failures of Direct-Acting Antiviral Therapy
por: Fierer, Daniel S, et al.
Publicado: (2020)

Adherence to Direct-Acting Antiviral Therapy in People Actively Using Drugs and Alcohol: The INCLUD Study
por: Brooks, Kristina M, et al.
Publicado: (2020)

Features of resistance-associated substitutions after failure of multiple direct-acting antiviral regimens for hepatitis C
por: Itakura, Jun, et al.
Publicado: (2020)

Durable Sustained Virologic Response After Oral Directly Acting Antiviral Therapy Despite Immunosuppressive Treatment
por: Hahn, Katherine J., et al.
Publicado: (2015)

Direct-Acting Antiviral Treatment Failure Among Hepatitis C and HIV–Coinfected Patients in Clinical Care
por: Rossi, Carmine, et al.
Publicado: (2019)

Immunological Predictors of Nonresponse to Directly Acting Antiviral Therapy in Patients With Chronic Hepatitis C and Decompensated Cirrhosis
por: Childs, Kate, et al.
Publicado: (2017)

Microelimination of Chronic Hepatitis C by Universal Screening Plus Direct-Acting Antivirals for Incarcerated Persons in Taiwan
por: Yang, Tsung-Hua, et al.
Publicado: (2020)

Direct-Acting Antiviral Treatment for Hepatitis C Genotypes Uncommon in High-Income Countries: A Dutch Nationwide Cohort Study
por: Isfordink, Cas J, et al.
Publicado: (2021)

Risk of Cardiovascular Events Among Patients Initiating Efavirenz-Containing Versus Efavirenz-Free Antiretroviral Regimens
por: Rosenblatt, Lisa, et al.
Publicado: (2016)

Real-World Effectiveness of Simeprevir-containing Regimens Among Patients With Chronic Hepatitis C Virus: The SONET Study
por: Alam, Imtiaz, et al.
Publicado: (2016)

Effectiveness of Direct-Acting Antiviral Therapy in Patients With Human Immunodeficiency Virus–Hepatitis C Virus Coinfection in Routine Clinical Care: A Multicenter Study
por: Kim, H Nina, et al.
Publicado: (2019)

Absolute Insurer Denial of Direct-Acting Antiviral Therapy for Hepatitis C: A National Specialty Pharmacy Cohort Study
por: Gowda, Charitha, et al.
Publicado: (2018)

Predictors of Hepatitis C Treatment Failure After Using Direct-Acting Antivirals in People Living With Human Immunodeficiency Virus
por: Cachay, Edward R, et al.
Publicado: (2019)

T-cell Activation Is Correlated With Monocyte Activation in HCV/HIV Coinfection and Declines During HCV Direct-Acting Antiviral Therapy
por: Auma, Ann W N, et al.
Publicado: (2021)

Development of Hepatocellular Carcinoma in Patients Aged 75–84 Years With Chronic Hepatitis C Treated With Direct-Acting Antivirals
por: Ogawa, Eiichi, et al.
Publicado: (2020)

The Hepatitis C Care Cascade During the Direct-Acting Antiviral Era in a United States Commercially Insured Population
por: Ferrante, Nicole D, et al.
Publicado: (2022)

The Impact of Direct-Acting Antivirals in the Hepatitis C-Sustained Viral Response in Human Immunodeficiency Virus-Infected Patients With Ongoing Barriers to Care
por: Cachay, Edward R., et al.
Publicado: (2015)

Antiretroviral Use in the CEASE Cohort Study and Implications for Direct-Acting Antiviral Therapy in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection
por: Martinello, Marianne, et al.
Publicado: (2016)

Hepatitis B Virus Reactivation in Patients Receiving Interferon-Free Direct-Acting Antiviral Agents for Chronic Hepatitis C Virus Infection
por: Liu, Chen-Hua, et al.
Publicado: (2017)

Knowledge, attitudes, and acceptability of direct-acting antiviral hepatitis C treatment among people incarcerated in jail: A qualitative study
por: Akiyama, Matthew J., et al.
Publicado: (2020)

Real-world Efficacy of Direct-Acting Antiviral Therapy for HCV Infection Affecting People Who Inject Drugs Delivered in a Multidisciplinary Setting
por: Alimohammadi, Arshia, et al.
Publicado: (2018)

Retrospective Study Demonstrating High Rates of Sustained Virologic Response After Treatment With Direct-Acting Antivirals Among American Indian/Alaskan Natives
por: Mera, Jorge, et al.
Publicado: (2019)

Persistence of Human Immunodeficiency Virus-1 Drug Resistance Mutations in Proviral Deoxyribonucleic Acid After Virologic Failure of Efavirenz-Containing Antiretroviral Regimens
por: De La Cruz, Justin, et al.
Publicado: (2019)

Changes in inflammatory biomarkers in HCV-infected patients undergoing direct acting antiviral-containing regimens with or without interferon
por: Mascia, Claudia, et al.
Publicado: (2017)

Real-World Outcomes of Direct-Acting Antiviral Treatment and Retreatment in United Kingdom–Based Patients Infected With Hepatitis C Virus Genotypes/Subtypes Endemic in Africa( )
por: Aranday-Cortes, Elihu, et al.
Publicado: (2021)

Clinical and Patient-Reported Outcomes of Direct-Acting Antivirals for the Treatment of Chronic Hepatitis C Among Patients on Opioid Agonist Treatment: A Real-world Prospective Cohort Study
por: Schulte, Bernd, et al.
Publicado: (2020)

Cytomegalovirus DNAemia Requiring (Val)Ganciclovir Treatment for More Than 8 Weeks Is a Key Factor in the Development of Antiviral Drug Resistance
por: Acquier, M, et al.
Publicado: (2023)

Rationale and design of a randomized controlled trial of varenicline directly observed therapy delivered in methadone clinics
por: Nahvi, Shadi, et al.
Publicado: (2014)

Hepatitis C Virus (HCV) Clearance After Treatment With Direct-Acting Antivirals in Human Immunodeficiency Virus (HIV)-HCV Coinfection Modulates Systemic Immune Activation and HIV Transcription on Antiretroviral Therapy
por: Ghiglione, Yanina, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ssbfu097eda580nk7d6me9vbvs